News and Treatment Updates

Abstract Venetoclax (VEN) combined with azacitidine (AZA) or low-dose cytarabine (LDAC) has significantly improved outcomes for older patients with acute myeloid leukemia (AML). However, severe cytopenia often leads to treatment interruptions. Previous literature has reported…

Key Takeaways Subgroup ORRs in NPM1-mutated AML were highest with FLT3+IDH1/2 (75%) and IDH1/2 (71.4%), with CR/CRh enrichment in these molecular subsets. MRD negativity frequently accompanied remissions in NPM1-mutated AML (64.3% of evaluable CR/CRh), but TP53 co-mutations…

VEXAS syndrome is a clonal hemato-inflammatory disorder impacting older, predominantly male patients, characterized by systemic inflammation and progressive bone marrow failure. It is caused by somatic mutations in UBA1, an X-linked gene, essential for initiating cellular…

The timing of TP53 mutation acquisition carries important prognostic implications for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes/MPN overlap disorders. Later emergence of the mutation is associated with significantly worse survival outcomes…

Abstract Background For patients with acute myeloid leukemia (AML) who are 75 years of age or older or who are ineligible for intensive induction chemotherapy, azacitidine or decitabine plus venetoclax is the standard of care, but parenteral administration imposes a burden on…

A blood cancer survivor debunks the movie myth of a quick cure, exposing the harsh, lasting side effects that remain after ringing the bell. One phrase I get tired of hearing lately is that something is a process. This word is often over-used and applies to anything from life…

TP53-mutated (TP53-mt) myelodysplastic syndromes (MDS) are aggressive myeloid neoplasms associated with inferior responses to conventional chemotherapy and a high risk of progression to acute myeloid leukemia (AML).1-3 Although multiple targeted and immunotherapeutic strategies…

Key Points Frontline eltrombopag plus IST is cost-effective compared with IST alone for adults with severe aplastic anemia. Incremental net monetary benefit per patient treated with frontline eltrombopag is ∼$64 000. Abstract The randomized phase 3 RACE trial demonstrated…

Summary Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and…

Over the past several decades, there has been a consistent effort to move beyond the conventional “3+7” intensive induction regimen in the treatment of acute myeloid leukemia (AML). The advent of BCL-2 inhibitors has significantly transformed the therapeutic landscape…